Select Page

Beyond the gut: A new frontier in IBS treatment by targeting the brain

Beyond the gut: A new frontier in IBS treatment by targeting the brain

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may alleviate IBS symptoms by acting directly on the central nervous system. Using a novel stress-induced mouse model, they found these drugs reduce abdominal pain and regulate bowel movements. This research suggests a promising approach to treating IBS by targeting stress as a contributing factor.

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.

Leave a reply

Your email address will not be published. Required fields are marked *